A5058631533- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Antifungal resistance and susceptibility
- Probiotics and Fermented Foods
- Integrated Circuits and Semiconductor Failure Analysis
- Multiple Myeloma Research and Treatments
- Bacterial Identification and Susceptibility Testing
- Peptidase Inhibition and Analysis
- Airway Management and Intubation Techniques
- Glioma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- T-cell and Retrovirus Studies
- Silicon Carbide Semiconductor Technologies
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Inhalation and Respiratory Drug Delivery
- Antimicrobial Resistance in Staphylococcus
- Viral-associated cancers and disorders
- Herbal Medicine Research Studies
University Hospital Heidelberg
2023-2025
Heidelberg University
1991-2025
Johannes Gutenberg University Mainz
2014
Abstract Allogeneic hematopoietic cell transplantation (alloHCT) is an effective treatment for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), but the contribution of conditioning regimen still unclear. Here we present a retrospective single-center study using intermediate-dose total body irradiation (TBI) and fludarabine alloHCT in PTCL. Forty-seven underwent PTCL between 2010 2023 after TBI (8 Gy 87% cases). In most was administered as part second-line therapy, 22...
Immunomodulation is an important part of lenalidomide's mode action. We analyzed the impact lenalidomide on T cells from patients with multiple myeloma during therapy in vivo and lenalidomide-refractory disease vitro Patients enrolled German Speaking Myeloma Multicenter Group (GMMG) MM5 trial received a consolidation two cycles after autologous stem cell transplantation (ASCT). Half study population continued treatment maintenance for 2 y, while other until complete remission. 58 (n = 30) or...
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two prior treatment lines, but real-world data scarce. In this retrospective, multicenter, multinational study, we evaluated the outcomes of 70 patients with r/r DLBCL treated glofitamab as part compassionate use patient program in DACH region (Germany, Austria, Switzerland). The median number lines was four, 71% having received CAR-T therapy,...
The main problem encountered with serodiagnostic tests for Candida infections is their failure to differentiate between invasive and superficial candidosis. Recent immunoblotting studies suggested that the use of selective somatic proteins albicans as antigens might be a promising approach toward developing new generation assays. In this study major cytoplasmic protein molecular weights 47,000 (47K), 46,000 (46K), 45,000 (45K), 29,000 (29K) were identified potential marker antibody detection...
Skeletal involvement (SI) is observed at low prevalence in patients with diffuse large B-cell lymphoma (DLBCL). Due to the rareness of this particular condition, prospective trials for these are scarce.We analyzed clinical characteristics and outcome 75 DLBCL SI order identify factors prognostic impact towards progression-free survival (PFS) overall (OS).Limited stage disease (Ann Arbor IE-IIE) was present 34 (45%), 41 (55%) had advanced IIIE-IVE). Outcome generally favorable 3-year OS 83%....
Renal involvement in patients with lymphoma is rare but associated poor prognosis. We analyzed characteristics and outcome of 22 newly diagnosed diffuse large B-cell (DLBCL) renal treated a rituximab-containing regimen curative intent. The majority presented advanced disease, 86% were Ann Arbor stage ≥ III had an IPI score 3. impairment was present 32%. Outcome three-year progression-free survival (PFS) 44% overall (OS) 52% significantly worse compared to DLBCL without (p < 0.01). Patients...
Die Verneblertherapie gilt bei schweren oder exazerbierenden Atemwegserkrankungen als relevante Option (GOLD Guidelines 2013), da sie keine spezielle Inhalationstechnik des Patienten erfordert. klinische Wirkung wird wesentlich durch die Aerosolperformance Verneblergeräts bestimmt. Ziel dieser Untersuchung war, mit 2 anerkannten Simulationsmodellen von marktüblichen kompressorbetriebenen Verneblern zu vergleichen.